PP
KNTE

PDT Partners’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

PDT Partners’s Portfolio KNTE Stock Details KNTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-18,419
Closed -$115K – 683
2023
Q1 		$115K Buy
+18,419
New +$112K 0.02% 531

Other funds holding KNTE

FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PDT Partners's KNTE Position: Q2 2023 in Review

PDT Partners sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q2 2023, closing a stake of 18,419 shares — an estimated $115K sold.

PDT Partners first reported a position in KNTE in Q1 2023 and held it in 1 quarter. The position peaked at $115K in Q1 2023. 72 funds tracked by Wall St. Rank hold KNTE as of Q2 2023.

  • PDT Partners reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • PDT Partners sold 18,419 Kinnate Biopharma Inc. Common Stock shares in Q2 2023, an estimated $115K.
  • PDT Partners first reported a position in Kinnate Biopharma Inc. Common Stock in Q1 2023 and held it in 1 quarter.
  • PDT Partners's Kinnate Biopharma Inc. Common Stock position peaked at $115K in Q1 2023.
  • 72 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q2 2023.

Based on PDT Partners's 13F filing for Q2 2023, filed 14 Aug 2023.